Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients / 中华外科杂志

Recently, prostate cancer has become the most common male urological cancer worldwide. However, it was difficult for the currently widely available imaging modalities to precisely diagnose this disease. With the development of nuclear medical technology, molecular imaging targeting prostate specific membrane antigen has been introduced into China. To promote the standardization of this imaging modality, the experts consensus was published by Chinese Anticancer Association Genitourinary Oncology Committee and recommendations for its application in the diagnosis and treatment of prostate cancer were attached, which would be helpful for doctors who are conducting or preparing for this examination.

Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition / 中华外科杂志

The prevalence of prostate cancer has shown a marked increase in China. Most patients are presented with metastasis at diagnosis.It has been proven by clinical trials that besides androgen deprivation therapy, Abiraterone and docetaxel can improve the overall survival of metastatic hormone sensitive prostate cancer patients with high risks.For metastatic castration-resistant prostate cancer treatment, docetaxel, abiraterone and enzalutamide, etc., have demonstrated significant overall survival benefit. Among them, docetaxel and abiraterone have accumulated adequate experience in Chinese patients. Therefore, it is quite important for Chinese physicians to make reasonable clinical decisions based on these treatment regimes. In order to improve patients' survival and life quality, Chinese Anticancer Association Genitourinary Oncology Committee composed this expert consensus to help physicians to make reasonable decisions.